Elizabeth Degrush, DO
Basic profileUniversity of Massachusetts Chan Medical School
Elizabeth Degrush is a Psychiatry physician affiliated with University of Massachusetts Chan Medical School. OpenAlex indexes 10 publications with 366 citations (h-index 7); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
33 Lyman St
Westborough, MA 015811404
Telephone
508-898-0055Provider last certified this registry record 22 Nov 2020.
Clinical trials
- Endothelial Facilitation in Alzheimer's Disease
Sponsor: University of Massachusetts, Worcester
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
24 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202525 payments
- PFIZER INC.Program year20259 payments
- Teva Pharmaceuticals USA, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
93%SSRI13.8%Sertraline Hcl33%Trazodone Hcl26%Fluoxetine Hcl20%Escitalopram Oxalate8%Citalopram Hbr6%Paroxetine Hcl5%Fluvoxamine Maleate3%Part D<11 patientsBenzodiazepine12.5%Clonazepam48%Lorazepam34%Diazepam12%Alprazolam6%Part D<11 patients+ 26 more classes in this area
Cardiovascular
4.5%Beta blocker1.8%Propranolol Hcl100%Part D<11 patientsCentral alpha-2 Adrenergic Agonist1.7%Clonidine Hcl76%Clonidine Hcl Er25%Part D<11 patients+ 2 more classes in this area
Blood & clotting
1.5%Salt solutions1.1%Sodium Chloride100%Part D<11 patientsSolutions for parenteral nutrition0.4%Calcium Acetate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Impact of AD Drug Treatments on Event-Related Potentials as Markers of Disease Conversion
Current Alzheimer Research
2013 - C145 as a Short-Latency Electrophysiological Index of Cognitive Compensation in Alzheimer's Disease
Journal of Alzheimer s Disease
2012
Similar KOLs
Other experts from the same institution or the same specialty.
Fernando Martinez, MD
University of Massachusetts Chan Medical School
Joel Gore, MD
University of Massachusetts Chan Medical School
Johanna Seddon, MD
University of Massachusetts Chan Medical School
Andres Schanzer, MD
University of Massachusetts Chan Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”